DETERMINATION OF TOXICITY INDICATORS OF THE NEW ANTIMASTITIS DRUG BASED ON PREDNISOLON AND CEFQUIN SULFATE
Abstract
Cow mastitis is one of the main problems of dairy farming. Diseases of cows with mastitis cause large financial losses for dairy farms. Fats cause a decrease in the productivity of animals and a decrease in the quality of milk. Milk obtained from sick animals cannot be sent for free sale, due to which farms will not receive products. Antibiotics are most often used to treat cows with mastitis. As a result of their incorrect use, without taking into account the sensitivity of microorganisms to antibiotics, the phenomenon of antibiotic resistance arises, which worries scientists all over the world. An important element of the strategy for combating mastitis in cows is the development of new drugs to which the microorganisms that cause mastitis in cows have not yet developed antibiotic resistance. Our research is aimed at the development and introduction into production of a new antimastitis drug based on prednisone and cefquin sulfate, namely the study of acute and chronic toxicity. Research was carried out on the basis of the Department of Veterinary Expertise, Microbiology, Zoohygiene and Safety and Quality of Livestock Products of the Faculty of Veterinary Medicine in the "Veterinary Pharmacy" laboratory of the Sumy National Agrarian University. Cefquinum sulfate and prednisolone were used as a basis for the development of this tool. Cefquin belongs to the IV generation of cephalosporin antibiotics. Cefquin has a bactericidal effect against G-positive and G-negative, aerobic, anaerobic, facultatively anaerobic microorganisms. For the second component of the drug, prednisolone was used, which belongs to the group of synthetic glucocorticoids, it has anti-inflammatory, anti-allergic, anti-exudative, anti-edematous, desensitizing and anti-toxic properties. The methods of H. Kerber (1931) and H. Pershin (1950) were used to establish toxicity parameters. Data analysis shows that the toxic effect of Sulfacef drug on experimental rats begins at a dose of 1200 mg/kg. As a result of the calculation according to the method of Kerber and Pershyn, the acute toxicity of the drug Sulfacef when administered intragastrically to rats was 1610 mg per kg of weight. The results of both studies turned out to be identical, which indicates their reliability. It has been established that the anti-mastitis drug Sulfacef based on prednisone and cefquin sulfate, according to Sanitary and Hygienic Standards and SOU 85.2-37-736:2011, belongs to the third class of danger (moderately dangerous compounds).
References
2. Aliiev, E., Paliy, A., Kis, V., Paliy, A., Petrov, R., Plyuta, L., Chekan, O., Musiienko, O., Ukhovskyi, V., & Korniienko, L. (2022). Establishing the influence of technical and technological parameters of milking equipment on the efficiency of machine milking. Eastern-European Journal of Enterprise Technologies, 1(1 (115), 44–55. https://doi.org/10.15587/1729-40 61.2022.251172
3. Berezovskyi, A. V., & Dovbnya, A. О. (2023). Study of toxicity indicators of the new anti-masti drug based on iodine compounds. Bulletin of Sumy National Agrarian University. The Series: Veterinary Medicine, (3(58), 9-15. https://doi.org/10.32845/bsnau.vet.2022.3.2
4. Berezovskyi, A., Dovbnya, A., Fotin, O., Kisil, D., & Morozov, B. (2023). Rationale for the prevention of mastitis in cows during the dry period and after calving. Scientific Horizons, 26(4), 43-53. https://doi.org/10.48077/scihor4.2023.43
5. Biggs, A. (2017). Update on dry cow therapy 1. antibiotic v non-antibiotic approaches. In Practice. 39:255–72.
6. Bradley, A.J. (2002). Bovine mastitis: An evolving disease. Vet. J. 164:116–128. doi: 10.1053/tvjl.2002.0724.
7. Doklinichni doslidzhennia veterynarnykh likarskykh zasobiv: [Preclinical studies of veterinary medicinal products] / Ed. I.Y. Kotsyumbas. Lviv: Triada plus, 2006, 360 p. (in Ukrainian)
8. Dovbnia, A., Berezovskiy, A., & Fotina, H. (2019). Dynamics of cow mastitis disease in conditions of industrial milk production. Scientific Messenger of LNU of Veterinary Medicine and Biotechnologies. Series: Veterinary Sciences, 21(96), 171-176. https://doi.org/10.32718/nvlvet9630
9. El Hafez, S.M.A., Ismael, A.B., Mahmoud, M.B., Elaraby, A-KA. (2013). Development of new strategy for non-antibiotic therapy: bovine lactoferrin has a potent antimicrobial and immunomodulator effects. Adv Infect Dis.; 3:185–92. doi: 10.4236/aid.2013.33027.
10. Fratini, F., Casella, S., Leonardi, M., et al. (2014). Antibacterial activity of essential oils, their blends and mixtures of their main constituents against some strains supporting livestock mastitis. Fitoterapia. 96:1–7. doi: 10.1016/j.fitote.2014.04.003.
11. Hadzevych, O.V., Paliy, A.P., Kinash, O.V., Petrov, R.V., Paliy, A.P. (2019). Antibiotic resistance of microorganisms isolated from milk. World of medicine and biology, 3(69), 2245-250 https://doi.org/10.26724/2079-8334-2019-3-69-245-250.
12. Halasa, T, Huijps, K, Østerås, O, Hogeveen, H. (2007). Economic effects of bovine mastitis and mastitis management: a review. Vet Q 29(1):18–31. https://doi.org/10.1080/01652176.2007.9695224
13. Król, J., Brodziak, A., Litwińczuk, Z., Litwińczuk, A. (2013). Effect of age and stage of lactation on whey protein content in milk of cows of different breeds. Pol J Vet Sci. 16:395–7. doi: 10.2478/pjvs-2013-0055.
14. Kumar, G.S.N., Apannavar, M.M., Surnagi, M.D., Kotresh, A.M.. (2010). Study on incidence and economics of clinical mastitis. Karnataka J Agric Sci. 23:407–408.
15. Liang, D., Li, F., Fu, Y., et al. (2014). Thymol inhibits LPS-stimulated inflammatory response via down-regulation of NF-κB and MAPK signaling pathways in mouse mammary epithelial cells. Inflammation. 37:214–22. doi: 10.1007/s10753-013-9732-x.
16. Lopes, T.S., Fontoura, P.S., Oliveira, A., Rizzo, F.A., Silveira, S., Streck, A.F. (2020). Use of plant extracts and essential oils in the control of bovine mastitis. Res. Vet. Sci. 131:186–193. doi: 10.1016/j.rvsc.2020.04.025.
17. McDermott, P.F., Zhao, S., Wagner, D.D., Simjee, S., Walker, R.D., White, D.G. (2002). The food safety perspective of antibiotic resistance. Anim Biotechnol. May;13(1):71–84.
18. Neculai-Valeanu, A.S., Ariton, A.M., Mădescu, B.M., Rîmbu, C.M., Creangă, Ş. (2021). Nanomaterials and essential oils as candidates for developing novel treatment options for bovine mastitis. Animals. 11:1625. doi: 10.3390/ani11061625.
19. Palii, А.P., Osipenko, T.L., Chigiryov, V.A., Gurko, I.Y., Petrov, R.V., Berezovsky, A.V., Khitska, O.A., Furman, S.V., Lisohurska, D.V., Lisohurska, O.V. (2021). Influence of the fixed "father" factor on the protein content in milk and the yield of milk protein in cattle. Ukrainian Journal of Ecology,11 (3), 353-359. https://doi.org/10.15421/20 21_ 183
20. Pedersen R.R., Krömker V., Bjarnsholt T., Dahl-Pedersen K., Buhl R., Jørgensen E. (2021). Biofilm research in bovine mastitis. Front. Vet. Sci. 2021;8:656810. doi: 10.3389/fvets.2021.656810.
21. Pro zatverdzhennia Poriadku provedennia naukovymy ustanovamy doslidiv, eksperymentiv na tvarynakh.[ On the approval of the Procedure for carrying out trials and experiments on animals by scientific institutions]. (2012). Access mode:https://zakon.rada.gov.ua/laws/show/z0416-12#Text. (in Ukrainian)
22. Ricci, A., Allende, A., Bolton, D., et al. (2017). Risk for the development of Antimicrobial Resistance (AMR) due to feeding of calves with milk containing residues of antibiotics. EFSA J. 2017;15:e04665. doi: 10.2903/j.efsa.2017.4665.
23. Shkromada, O., Palii, A., Palii, A., Skliar, O., Dudchenko, Yu., & Nedzheria, T. (2019). Pidvyshchennia yakosti moloka za rakhunok formuvannia mikroklimatu na tvarynnytskykh fermakh [Improving the quality of milk due to the formation of a microclimate on livestock farms]. Visnyk Sumskoho natsionalnoho ahrarnoho universytetu. Seriia: Veterynarna medytsyna, 4 (47), 43-49. https://doi.org/10.32845/bsnau.vet.2019.4.7 (in Ukrainian)
24. Steeneveld, W., van Werven, T., Barkema, H.W., Hogeveen, H.. (2011). Cow-specific treatment of clinical mastitis: an economic approach. J Dairy Sci. 94(1):174–188.
25. Suojala, L., Kaartinen, L., Pyörälä, S.. (2013). Treatment for bovine Escherichia coli mastitis - an evidence-based approach. J Vet Pharmacol Ther. 36(6):521–531.
26. Tezera, M. & Aman, Ali E. (2021). Prevalence and associated risk factors of Bovine mastitis in dairy cows in and around Assosa town, Benishangul-Gumuz Regional State, Western Ethiopia. Vet. Med. Sci. 7:1280–1286. doi: 10.1002/vms3.454.
27. Tomanić, D., Samardžija, M. & Kovačević, Z. (2023). Alternatives to Antimicrobial Treatment in Bovine Mastitis Therapy: A Review. Antibiotics, 12(4), 683. http://dx.doi.org/10.3390/antibiotics12040683
28. Ungemach, F.R., Müller-Bahrdt, D., Abraham, G. (2006). Guidelines for prudent use of antimicrobials and their implications on antibiotic usage in veterinary medicine. Int J Med Microbiol. Jun;296(Suppl 41):33–8.
29. Vakkamaki, J., Taponen, S., Heikkila, A. M., & Pyorala, S. (2017). Bacteriological etiology and treatment of mastitis in Finnish dairy herds. Acta Veterinaria Scan-dinavica. 59 (1), 33. doi: 10.1186/s13028-017-0301-4.
30. WHO. World Health Organization: Antimicrobial Resistance: Global Report on Surveillance. WHO, Geneva, Switzerland: (2014). Available online at: http://www.who.int/drugresistance/documents/surveillancereport/en/
ISSN 
ISSN 
